NEW YORK / Apr 25, 2023 / Business Wire / DocGo, a leading provider of last-mile mobile health services (Nasdaq: DCGO), today announced that the company will report results for the first quarter ended March 31, 2023, after the markets close on Monday, May 8th. Management will host a conference call for analysts and investors at 5:00pm ET on that day.
Conference call and webcast details:
Monday, May 8th, 5:00pm EDT
1-877-407-0784 (U.S.)
1-201-689-8560 (international)
Conference ID: 13737381
To access the Call me™ feature, which avoids the need to wait for an operator, click here.
The webcast can be accessed under Events on the Investors section of the company’s website, https://ir.docgo.com/.
About DocGo
DocGo is a leading provider of last-mile mobile care services. DocGo is disrupting the traditional four-wall healthcare system by providing high quality, highly affordable care to patients where and when they need it. DocGo's innovative technology and dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for facilities, hospital networks, and health insurance providers. With Mobile Health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote physician, in the comfort of a patient's home or workplace. Together with DocGo's integrated Ambulnz medical transport services, DocGo is bridging the gap between physical and virtual care. For more information, please visit www.docgo.com.
Last Trade: | US$3.00 |
Daily Change: | -0.05 -1.64 |
Daily Volume: | 1,058,934 |
Market Cap: | US$304.590M |
February 27, 2025 February 19, 2025 February 10, 2025 December 18, 2024 December 10, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MORETerns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREEnd of content
No more pages to load